Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies.
Clin Liver Dis
; 26(4): 705-726, 2022 11.
Article
em En
| MEDLINE
| ID: mdl-36270725
ABSTRACT
Primary biliary cholangitis (PBC) is an autoimmune disease of the interlobular bile ducts leading to secondary damage of hepatocytes and may progress to cirrhosis and liver failure. The first-line treatment is ursodeoxycholic acid; up to 40% of patients do not have an adequate response and remain at risk of disease progression. Obeticholic acid has been conditionally approved for the treatment of PBC as add-on therapy and bezafibrate has shown similar efficacy in this group of patients. Several new therapies are in development and may further add to the treatment options available to patients with PBC.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Colangite
/
Cirrose Hepática Biliar
Limite:
Humans
Idioma:
En
Revista:
Clin Liver Dis
Assunto da revista:
GASTROENTEROLOGIA
Ano de publicação:
2022
Tipo de documento:
Article